Overview
Plerixafor, marketed under the brand name Mozobil, is a small molecule drug that acts as a CXCR4 chemokine receptor antagonist. It was developed for hematopoietic stem cell mobilization in patients with multiple myeloma or non-Hodgkin's lymphoma who are undergoing autologous transplantation. The compound works by disrupting the CXCR4/SDF-1 axis, which normally retains stem cells in the bone marrow. This mechanism allows for the efficient collection of stem cells from peripheral blood, making it a crucial component in stem cell transplantation protocols.
Physical and Chemical Properties
Plerixafor is a bicyclam derivative with a molecular weight of 502.79 g/mol. It appears as a white to off-white powder that is soluble in both water and organic solvents like DMSO. The compound is typically supplied as a lyophilized powder for injection after reconstitution with sterile water. The drug demonstrates stability under recommended storage conditions (2-8°C) but should be protected from light and moisture. Its chemical structure features multiple nitrogen-containing rings that contribute to its specific binding affinity for the CXCR4 receptor.
Main Applications
The primary medical use of plerixafor is in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in cancer patients. This application is particularly important for patients who fail to mobilize sufficient stem cells with G-CSF alone. Research is ongoing for other potential applications, including treatment of WHIM syndrome (a rare immunodeficiency disorder) and as an adjunct in HIV therapy due to its ability to block HIV entry into cells. Some studies are also investigating its potential in cancer treatment by disrupting tumor microenvironments.
Safety and Storage
Plerixafor should be handled as a hazardous pharmaceutical compound. Appropriate personal protective equipment, including gloves and safety glasses, should be worn when handling the powder or solution. The drug is typically administered by healthcare professionals in clinical settings. For storage, maintain the lyophilized powder at refrigerated temperatures (2-8°C) in its original packaging to protect from light. Once reconstituted, the solution should be used immediately or stored for no more than 24 hours at 2-8°C. Proper disposal methods should be followed for any unused portions.
B2B Procurement Guide
When procuring plerixafor for medical or research purposes, it's essential to work with authorized pharmaceutical distributors who can provide proper documentation of the drug's chain of custody. The product should be shipped with appropriate cold chain logistics to maintain potency. Buyers should verify the supplier's Good Distribution Practice (GDP) certification and ensure the product comes with full analytical documentation, including certificates of analysis. Due to the high cost and specialized nature of this drug, many institutions establish long-term contracts with reliable suppliers to ensure consistent access.
Related Manufacturers
- 主营：橡胶油、白芷油、7782-92-5、泊沙康唑主环、pbtcaona4、艾叶油、二甲基、桉树醇、2905-60-4、5989-81-1、重质苯、活性炭、1305-62-0、1192-62-7、安息油、9005-32-7、正辛烷、7775-27-1、8050-09-7、1739-84-0、7786-30-3、黄糊精、6920-22-5、三辛胺、1897-52-5、7727-21-1